WASHINGTON, D.C. - The Association for the Accreditation of Human Research Protection Programs today announced that it has accredited four more research organizations, including its first organizations in Africa and South America. The newly accredited organizations are:
“Even more important, however, is what these accreditations mean to the global research community,” she added. “In the U.S. and overseas, more and more organizations are committing to AAHRPP’s standards for research ethics, quality and safety. That’s good news for research participants, researchers, sponsors and all who ultimately will benefit from the discoveries that research makes possible.”  “Each of these accreditations represents a ‘first’ for us,” AAHRPP President and CEO Elyse I. Summers said. “Today we enthusiastically add great geographic and substantive diversity to our family of AAHRPP-accredited organizations, with our first organizations on the continents of Africa and South America, our first organization that focuses on traditional Chinese medicine and, believe it or not, our first accreditation in the state of New Jersey. To date, 231 organizations have earned AAHRPP accreditation. Of these, 35 are located outside the United States. To earn AAHRPP accreditation, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to high standards for research. In today’s global, collaborative research enterprise, organizations increasingly rely on AAHRPP accreditation status to help identify trusted research partners. AAHRPP has accredited organizations in 47 states, Belgium, Brazil, Canada, China, India, Mexico, Republic of Korea, Saudi Arabia, Singapore, South Africa, Taiwan and Thailand.All major U.S. independent institutional review boards have earned AAHRPP accreditation. In addition, more than 60 percent of U.S. research-intensive universities and over 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process. The National Institutes of Health, the world’s largest public funder of research, has earned accreditation, as has Pfizer, Inc., the largest industry sponsor of clinical research.
About AAHRPP
A nonprofit organization, AAHRPP provides accreditation for organizations that conduct or review human research and can demonstrate that their protections exceed the safeguards required by the U.S. government. To learn more, visit
www.aahrpp.org
.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.